Greater Bay Area (Guangdong): Hong Kong medicines and devices at designated hospitals
Designated institutions in mainland Guangdong may use certain Hong Kong-registered medicines and devices, each with Guangdong approval.
What this page covers. Rules and their official sources only, not whether a treatment works.
What the official sources say
- The National Medical Products Administration announced the regional regulatory innovation work plan in November 2020. Guangdong’s medical products regulator and health commission issued regional interim rules in August 2021. source
- The measure provides for urgent clinical use of certain Hong Kong-registered medicines and devices used in Hong Kong public hospitals, at designated Mainland institutions and subject to Guangdong approval. source
- The Guangdong Provincial Medical Products Administration accepts and reviews applications. The Hong Kong Drug Office reports 79 medicines, 100 devices and 71 designated institutions as of 30 September 2026. source
- The first designated providers included University of Hong Kong–Shenzhen Hospital, Modern Hospital Guangzhou, Guangzhou United Family Hospital, C-MER (Zhuhai) Dennis Lam Eye Hospital and Zhongshan Chenxinghai Hospital. source